This infographic provides a snapshot of Medicare and end-of-life care in California.
- view as grid
- view as list
This new fact sheet examines key questions around the potential changes President-elect Donald Trump and the next Congress may seek to make in Medicaid, a program that covers 73 million people nationally. Depending on how it is structured, a repeal of the Affordable Care Act could reverse the expansion of…
This fact sheet provides insight into how a repeal of the Affordable Care Act (ACA) and changes in the financing structure would affect Medicaid, including the Medicaid expansion, and how a Trump administration could change Medicaid through administrative actions.
This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader implications for Medicare of new high-priced drugs entering the market.
This Visualizing Health Policy infographic, produced in partnership with the Journal of the American Medical Association (JAMA), provides a snapshot of Medicare and end-of-life care.
This Visualizing Health Policy infographic, produced in partnership with the Journal of the American Medical Association (JAMA), provides a snapshot of Medicare and end-of-life care
Web Event: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs
On Wednesday, October 5, from noon to 1 p.m. ET, the Kaiser Family Foundation will host a web conversation to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted.
As policymakers in Washington scrutinize the rising cost of the EpiPen auto-injector, a new analysis from the Kaiser Family Foundation shows that Medicare Part D spending for the potentially life-saving device increased by more than 1000 percent between 2007, the year after the Part D drug benefit took effect, and…
This data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).